Shouyao Holdings (Beijing) Co. Ltd. A

The innovative drug sector opened lower on July 6 before climbing higher in choppy trade. Shouyao Holdings surged by the 20 percent daily limit, Maiwei Bio and Shutaishen jumped over 10 percent, BeiGene rose more than 6 percent, and Asymchem and Hengrui Medicine gained over 4 percent. On the news front, the General Office of the National Medical Products Administration recently sought public comments on a draft notice regarding optimizing the review and approval of cell and gene therapy drugs. The draft mentions supporting clinically driven innovation in cell and gene therapy drug development, focusing on key areas such as malignant tumors and rare diseases, encouraging global simultaneous development, and including eligible cell and gene therapy drugs in a 30-day review and approval channel for innovative drug clinical trials. A research note from Orient Securities noted that Chinese companies have recently made gradual breakthroughs in frontier fields such as cell therapy and AI-driven drug discovery. Several innovative drug makers have seen their core products enter the harvest stage, while medical insurance access, commercial insurance coverage, and cost ratio optimization are jointly driving continuous profit improvement.

China's A-share market saw mixed performance on July 6, with the Shanghai Composite Index edging down 0.06 percent to 4,041.24 points and the ChiNext Index falling 1.77 percent. Combined turnover on the two exchanges reached approximately 3.11 trillion yuan. The coal sector rallied in the afternoon, with Haohua Energy hitting its daily limit at the close, Xinji Energy surging nearly 9 percent, and Shaanxi Coal Industry climbing over 7 percent. The pharmaceutical sector was strong, with innovative drug concepts standing out. Shouyao Holdings briefly surged by the 20 percent daily limit, and Gan & Lee Pharmaceuticals hit its daily limit. The PCB concept slumped sharply, with Sinoma Science & Technology, China Jushi, and Haohua Science & Technology all hitting their daily limit down. Reports indicate that Nvidia's next-generation Kyber NVL144 rack architecture may face delivery delays of more than 12 months due to manufacturing process challenges with PCB mid-boards, pushing mass production back to 2028.